Dr. Sebastian Thams is a resident in neurology at Karolinska university hospital with focus on ALS and neuromuscular disorders. He has 10+ years of experience in basic and translational research, including a 4 year postdoc period at Columbia University motor neuron center, where he worked on small molecule screening and development of new drug candidates in ALS. Dr. Thams’ current research focuses on disease mechanisms and drug discovery in iPS-derived motor neurons from ALS patients with familial disease.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.